Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo

Figure 4 Lack of YSA specific targeting in nu/nu mice. A: 1 × 10¹¹ gc of Ad/∆F(FG)∆P (ablated, A) or 1 × 10¹¹ gc of Ad/∆F(FG)∆P-YSA (YSA; Y) are rapidly cleared from blood after intravenous (i.v.) and intraperitoneal (i.p.) administration into mice. At 10 min after i.v. or 90 min after i.p. injection and after 3 d (both), adenoviral genomic copies were determined in whole blood with real time PCR. B: Bio-distribution Ad/∆F(FG)∆P and Ad/∆F(FG)∆P-YSA injected i.v. or i.p. into nu/nu mice with a subcutaneous human pancreatic tumor. Animals were sacrificed 3 d after injection of 1 × 10¹¹ gc of adenoviral vector. All organs were harvested and analyzed for luciferase expression/mg of protein. (^aP < 0.05 compared with Ad/∆F(FG)∆P after i.v. injection; ^cP < 0.05 compared with Ad/∆F(FG)∆P after i.v. injection). C: The tumor/liver ratio of luciferase expression in each mouse demonstrates the lack of significant targeting of retargeted adenovirus to pancreatic cancer in vivo. D: Similar ASAT and ALAT levels in serum at 3 d after injection indicates comparable liver toxicity of ablated and retargeted adenoviral vectors in nu/nu mice. Data represent the mean ± SD of 4-7 mice.